Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta‐analysis
Authors' conclusion
Metformin did not reduce cancer incidence in RCTs involving subjects with overweight/obesity and/or prediabetes/diabetes.
Study context
- Population
- Adults with overweight/obesity and/or prediabetes/diabetes in randomized controlled trials (RCTs) of ≥24 weeks27 trials
- Participants
- 10,717 vs 10,003
- Comparison
- Metformin vs other interventions
- Metforminn = 10,717
- Controln = 10,003reference
- Outcome
- Cancer incidence (new diagnoses of cancer)
Methodological detailsrandom-effects model, trial sequential analysis, RoB 2.0, Grading of Recommendations, Assessment, Development and Evaluations (GRADE)
- Random-effects model
- Trial sequential analysis
- RoB 2.0
- GRADE
Pooled result
New cases of cancer
Relative risk
1.07
95% CI 0.87–1.31
Events by group
Metformin
170
events
Control
208
events
Metforminvs Control
RR 1.07 (95% CI 0.87–1.31)
As reported in the abstract
Further pooled results
Subgroups by study duration or effect of control intervention on weight
- Similar results in subgroup analyses
Risk of bias and publication bias
- Risk of bias low in most studies; no evidence of publication bias
Original publication
Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta‐analysis. Diabetes Obes Metab. Published 23 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →